Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12306566 | 1.00 | PRMT6 (0.43) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12306622 | 0.93 | PRMT6 (0.43) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13615620 | 0.83 | PRMT6 (0.41) | PRMT6P2RY12ADORA2AADORA2B | |
| SCHEMBL13722135 | 0.83 | KDM4E (0.36) | — | |
| SCHEMBL12306577 | 0.83 | ACHE (0.36) | ADORA2AADORA2B | |
| SCHEMBL12306600 | 0.83 | ACHE (0.36) | ADORA2AADORA2B | |
| SCHEMBL2719694 | 0.80 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12851855 | 0.80 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL12851647 | 0.80 | PRMT6 (0.46) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2312781 | 0.79 | PRMT6 (0.44) | PRMT6PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022193-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741457-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7399845-B2 | 6-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | FOUNDATION MEDICINE, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012281-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | PRMT6 627/4885PRKAB2 2020/4885PRKAG1 1355/4885 |
| US-20070249049-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | PRMT6 627/4885PRKAB2 2020/4885PRKAG1 1355/4885 |
| US-20100216979-A1 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, POLRMT, POLM | PRMT6 627/4885PRKAB2 2020/4885PRKAG1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.